Delos Capital — Full Portfolio
36 tracked investments · listed companies and verified rows first
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersQuan CapitalSR One Capital ManagementVivo Capital+1 more
Sirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area.
BiotechHealthtechLongevityMedical DevicesSan Diego, US
Qunsheng Ji(Chief Executive Officer)Curt Bradshaw(Chief Scientific Officer)Patrick Yue(Chief Medical Officer)Hailei Lu(Chief Financial Officer)
Co-investorsOrbiMedCreacion Ventures
Tulavi develops medical devices for peripheral nerve surgery, aiming to improve surgical treatment options and patient outcomes in nerve care.
HardwareHealthtechMedical DevicesMountain View, US
Farhad Khosravi(Executive Officer, Director)Fred Khosravi(Chairman & Co-Founder)Josh Vose(Chief Executive Officer)Corinne Bright(Executive Officer, Director)
BoardHenry Chen(Director)in
Co-investorsAscension Ventures
Verge Medical (formerly Ostial Corporation) develops medical devices for aorto-ostial vascular interventions, including the FLASH Flex aorto-ostial angioplasty system and the RoVo mechanical thrombectomy device, used by physicians for coronary and peripheral vascular cases.
HealthtechMedical Devices
Mike Buck(Chief Executive Officer)Adam Tschida(General Manager & COO)
Co-investorsAmed Ventures
STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients.
BiotechDeep TechHealthtechLongevityMedical Devices
Michael Luther(CEO)
Co-investorsAscension VenturesBreakout LabsBreakout VenturesNYBC VenturesKdT Ventures
Co-investorsAndera PartnersBioMedPartners
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira VenturesNextech Invest+8 more
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonRA Capital
Novel antiviral therapies with a lead program in HBV
Ablation catheter for the untreated atrial fibrillation market (acquired)
Atia Vision develops OmniVu, a modular shape-changing dual-optic intraocular lens (IOL) that uses the eye's natural accommodative mechanism to restore near, intermediate, and distance vision for cataract patients.
HardwareHealthtechMedical DevicesCampbell, US
Co-investorsAmed VenturesThe Capital Partnership
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Co-investorsForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMedQuan Capital+3 more
Averna Therapeutics is a biotechnology company developing therapeutics.
BiotechDeep TechHealthtechMedical DevicesWatertown, US
Thomas Barnes(Chief Executive Officer/President)Richard Morris(Chief Financial Officer)Thomas M. Barnes(CEO & Board Member)
BoardRoy Amariglio(Director)Nick Olsen(Director)Stephen Squinto(Director)in
Co-investorsDeep InsightNovartis Venture FundOrbiMed
Non-surgical, non-pharmacologic devices to induce weight loss
Co-investorsLongitude Capital
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)Michael Mendelsohn, M.D.(Founder)in
Co-investorsBain CapitalDigitalis VenturesNew Enterprise Associates (NEA)
Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities.
BiotechHealthtechChengdu
Peng Liang(Executive Officer, Director, Promoter)Joshua Liang(Executive Officer, Director)
BoardXiaodong Wang(Director)
Woburn, US
LAN BO CHEN(Executive Officer, Director)BRYAN KEANEY(Executive Officer)
BoardHENRY CHEN(Executive Officer, Director)in
Curatia Medical develops and manufactures FDA and CE-approved disposable medical devices for interventional procedures in cardiology, peripheral, neurology, and pulmonology.
Advanced ManufacturingHealthtechMedical DevicesSunnyvale, US
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPF-Prime CapitalSolasta VenturesAlexandria+7 more
Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.
HealthtechMedical DevicesCampbell, US
Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in
BoardJames Rogers(Director)Stacy Enxing Seng(Director)
Co-investorsAscension VenturesFemHealth VenturesLightstone Ventures
Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.
BiotechHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)inSteven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)in
BoardHenry Chen(Director)inTasneem Dohadwala(Director)in
Co-investorsAngel Physicians FundAscension VenturesExcelestar Ventures
Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects.
HealthtechMedical DevicesWoburn, US
Gregory H. Lambrecht(Director)Carey Hagan(Executive Officer, Director)Cary Hagan(Executive Officer, Director)
BoardRyan Drant(Director)inJeani Delagardelle(Director)Joshua Makower(Director)
Co-investorsNew Enterprise Associates (NEA)Questa CapitalGreenspring AssociatesNew Leaf Venture Partners
Liposeuticals develops proprietary formulations of sterile injectable drugs for hospital use, focusing on anesthesiology, oncology, and infectious disease treatments.
BiotechMedical Devices
Specialty pharma in dermatology and aesthetics for the Chinese market (acquired)
Phanes Therapeutics develops oncology and metabolic disease therapeutics targeting cell cycle regulators and related pathways.
BiotechDeep TechHealthtechMedical DevicesSan Diego, US
Dr. Ming Wang(Founder, President and CEO)
Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.
BiotechFemTechHealthtechMedical DevicesBedford, US
AMARPREET SAWHNEY(Executive Officer, Director, Promoter)inAmar Sawhney(Founder)NICK SVENCER(Executive Officer, Director, Promoter)FARHAD KHOSRAVI(Executive Officer, Director, Promoter)
BoardTARA BUTLER(Executive Officer, Director, Promoter)
Co-investorsAscension VenturesClavystBioFemHealth VenturesIyengar Capital PartnersAmed VenturesCatalyst Health Ventures
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)Simon Xi(Co-founder and CEO)Jackie Walling(CMO)Debasish Roychowdhury(Director)
Co-investorsVivo CapitalAMR Action FundBoehringer Ingelheim Venture FundKorea Investment PartnersLilly Asia VenturesMatrix Partners China
Co-investorsAisling CapitalAvoro Capital AdvisorsBioBritEcoR1 Capital
TRexBio develops Treg-focused biologic therapeutics for autoimmune and inflammatory diseases, using its Deep Biology Platform to analyze regulatory T cell behavior in human tissues and identify therapeutic targets.
AI & Machine LearningBiotechHealthtech
Co-investorsAvego BioScience CapitalPfizer Venture InvestmentsAgent Capital
Co-investorsAscension Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.